Madrigal Pharmaceuticals
MDGL
77 hedge funds and large institutions have $266M invested in Madrigal Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 14 reducing their positions, and 20 closing their positions.
179% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 14
12% more call options, than puts
Call options by funds: $4.83M | Put options by funds: $4.29M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 84 → 77 (-7)
17% less capital invested
Capital invested by funds: $320M → $266M (-$53.8M)
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$26.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.14M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.03M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.78M |
| 5 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$15M |
| 2 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$12.7M |
| 3 |
QF
QVT Financial
New York
|
-$11M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.8M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.09M |
MDGL Hedge Fund Activity: Q4 2013 in Review
77 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2013, worth a combined $266M — down 17% from $320M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of MDGL and 13 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 39 added.
The largest buyer was Caxton Corporation, adding an estimated $26.2M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $15M sold.
- 77 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2013, down from 84 in Q3 2013.
- Funds reported $266M of Madrigal Pharmaceuticals stock for Q4 2013, down 17% quarter-over-quarter.
- 13 funds opened new Madrigal Pharmaceuticals positions in Q4 2013 and 20 closed out, a net change of -7 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2013 was Caxton Corporation, an estimated $26.2M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2013 was Perceptive Advisors, an estimated $15M sold.
Based on aggregated 13F filings for Q4 2013.